Zobrazeno 1 - 10
of 152
pro vyhledávání: '"immunosuppressive cells"'
Publikováno v:
ImmunoTargets and Therapy, Vol Volume 13, Pp 775-788 (2024)
Wenjing Pan,1,* Zhaoyang Jia,1,* Jingtong Du,1,* Kexin Chang,2 Yiming Liu,2 Wei Liu,1 Xibo Zhao,3 Wenhua Tan1 1Department of Gynecology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, 150081, People’s
Externí odkaz:
https://doaj.org/article/33729f63b57341eb9daa631287b2c1a6
Autor:
Isabel Linares, Miguel Ángel Berenguer Frances, Rut Cañas, Dina Najjari, Cristina Gutiérrez, Susanna Marín, Silvia Comas, Ferran Guedea, Monica Pujol
Publikováno v:
BMC Immunology, Vol 24, Iss 1, Pp 1-11 (2023)
Abstract Background New combinations based on standard therapeutic modalities and immunotherapy require understanding the immunomodulatory properties of traditional treatments. The objective was to evaluate the impact of brachytherapy (BT) on the imm
Externí odkaz:
https://doaj.org/article/78f963e8add34964a0e5a3b186526635
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Externí odkaz:
https://doaj.org/article/45f478dcf2244630b3d358e1c082590f
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Zhenghou Zhang, Xiangyu Zhou, Jinshuai Guo, Fusheng Zhang, Yiping Qian, Guang Wang, Meiqi Duan, Yutian Wang, Haiying Zhao, Zhi Yang, Zunpeng Liu, Xiaofeng Jiang
Publikováno v:
Journal of Translational Medicine, Vol 20, Iss 1, Pp 1-23 (2022)
Abstract As an important component of the immunosuppressive tumor microenvironment (TME), it has been established that mesenchymal stem cells (MSCs) promote the progression of tumor cells. MSCs can directly promote the proliferation, migration, and i
Externí odkaz:
https://doaj.org/article/cc1ac325bc044228ab93e54afb02ea10
Publikováno v:
Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-33 (2022)
Abstract Immunotherapies like the adoptive transfer of gene-engineered T cells and immune checkpoint inhibitors are novel therapeutic modalities for advanced cancers. However, some patients are refractory or resistant to these therapies, and the mech
Externí odkaz:
https://doaj.org/article/274a447483bf40e79ac6103100cdf0e6
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
The tumor microenvironment (TME) is implicated in tumorigenesis, chemoresistance, immunotherapy failure and tumor recurrence. Multiple immunosuppressive cells and soluble secreted cytokines together drive and accelerate TME disorders, T cell immunode
Externí odkaz:
https://doaj.org/article/4eb1872c24644b2eab8ff95cae26f040
Autor:
Robby Barnestein, Loïck Galland, Laura Kalfeist, François Ghiringhelli, Sylvain Ladoire, Emeric Limagne
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
With the rapid clinical development of immune checkpoint inhibitors (ICIs), the standard of care in cancer management has evolved rapidly. However, immunotherapy is not currently beneficial for all patients. In addition to intrinsic tumor factors, ot
Externí odkaz:
https://doaj.org/article/abb353e1cf2545e0aea96456bf5eb7f2
Autor:
Xuehua Zhang, Leilei Zhao, He Zhang, Yurui Zhang, Huanyu Ju, Xiaoyu Wang, Huan Ren, Xiao Zhu, Yucui Dong
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Glioblastoma multiforme (GBM) is the most malignant intracranial tumor in adults, characterized by extensive infiltrative growth, high vascularization, and resistance to multiple therapeutic approaches. Among the many factors affecting the therapeuti
Externí odkaz:
https://doaj.org/article/31e313d9f4dc4318b4b68bf7549bc383
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
The most common bone cancer is osteosarcoma (OS), which mostly affects children and teenagers. Early surgical resection combined with chemotherapy significantly improves the prognosis of patients with OS. Existing chemotherapies have poor efficacy in
Externí odkaz:
https://doaj.org/article/4a60fbf8deab4b2aa26fed3ca8edb0f2